網頁

星期三, 12月 01, 2021

麻州州長查理貝克證實將不參選連任

        (Boston Orange 周菊子綜合報導) 麻州2021年底的震撼彈,州長查理貝克(Charlie Baker)告訴朋友,2022年他不參選連任了。

                 麻州州長週一 (1129)時上GBH廣播節目時說,他很快就會做決定,今天週三 (121)就爆出查理貝克不參選下任州長的消息,然後這消息也被證實了。正參選麻州稽核長 (Audit) Chris Dempsey 也在今日發給支持者的電郵中說,查理貝克決定不選連任了。

                  現在是2021121日,距離2022年的州級選舉,其實還有大約一年。但近年有意角逐職位者,佈署行動都越來越早。麻州州長一職就早從今年初就有人宣佈參選,迄今已累計至少6人參選,其中知名度較高的有麻州參議員陳翟蘇妮 (Sonia Chang Diaz),哈佛教授 Danielle Allen,曾任麻州參議員的Ben Downing,以及共和黨籍曾任麻州眾議員的Geogg Diehl

不過最有實力,民調支持度最高的麻州現任州長查理貝克,還有一直被人認為是麻州州長未來人選的民主黨籍麻州總檢察長奚莉 (Maura Healey),在到底是否參選下屆州長這問題上,卻一直不肯鬆口。

英文報章一直不斷猜測,前天波士頓環球報還有一篇文章談論這事,認為查理貝克應該以獨立無黨派身分參選第三任。

今天,消息卻爆了出來,民調支持度迄今仍然有70%,保持著歷來最高紀錄的州長查理貝克透露,後來也證實,2022年他不競選第三度連任,放棄了打破麻州州長從未在位超過2任這歷史紀錄的機會。

其實幾乎所有人都認為,只要查理貝克決定參選,一定可以輕鬆連任。雖然並不是完全沒人批評他,包括幾名參選人都說麻州族裔不平等,貧富差距大,也有人批評他缺乏遠見,改善得很慢,沒有充分利用麻州豐富的資源,但大部分的人都稱讚能夠因應地方需求,願意和民主黨妥協,把麻州經濟帶到高點,新冠病毒大流行發生前,麻州的失業率僅只3%。今年五月,美國總統拜登(Joe Biden)也稱讚查理貝克做得好。

查理貝克的不參選連任決定,對明年的州長選舉,勢必產生重大影響。在位期間一直非常活躍,能見度打破麻州副州長紀錄的共和黨籍白莉朵Karyn Polito,也表示不競選連任。(更新版)

From Twitter

Our plan

Governor Baker and Lt. Governor Polito

 To Our Friends & Colleagues –

After several months of discussion with our families, we have decided not to seek re-election in 2022. This was an extremely difficult decision for us. We love the work, and we especially respect and admire the people of this wonderful Commonwealth. Serving as Governor and Lieutenant Governor of Massachusetts has been the most challenging and fulfilling jobs we’ve ever had. We will forever be grateful to the people of this state for giving us this great honor.

We have all been going through an extraordinarily difficult pandemic, and the next year will be just as important, if not more important, than the past year. We have a great deal of work to do to put the pandemic behind us, keep our kids in school, and keep our communities and economy moving forward. That work cannot and should not be about politics and the next election. If we were to run, it would be a distraction that would potentially get in the way of many of the things we should be working on for everyone in Massachusetts. We want to focus on recovery, not on the grudge matches political campaigns can devolve into.

Coming out of this pandemic, we are acutely aware, more than ever before, about how little we can take for granted when it comes to our family, our friends, or our time on this planet. Done right, these jobs require an extraordinary amount of time and attention, and we love doing them. But we both want to be there with Lauren and Steve and our children for the moments, big and small, that our families will experience going forward.

When the voters of this great Commonwealth gave us this opportunity to serve, we had plans. Lots of them. They didn’t include 30 days of snow in our first 60 days in office. Or a natural gas explosion. Or a global pandemic. But with your support, and the creativity and resilience of the people of Massachusetts, we worked through these and other unanticipated crises and events to move our state forward.

We are determined to continue to put aside the partisan playbook that dominates so much of our political landscape — to form governing partnerships with our colleagues in local government, the Legislature, and the Congressional delegation. That bipartisan approach, where we listen as much as we talk, where we focus our energies on finding areas of agreement and not disagreement, and where we avoid the public sniping and grandstanding that defines much of our political discourse, allows us to make meaningful progress on many important issues.

We’ve led the nation in battling the opioid crisis, with more to do and the resources to do it. Our energy future — the nation’s energy future — is cleaner and more cost effective because of our work on deep water offshore wind. We brought broadband to our friends and neighbors in Western Massachusetts. We’ve made historic investments in housing of all kinds, enacted a landmark law to battle our housing crisis, and anticipate using significant federal funding to level the housing playing field going forward. We secured landmark criminal justice and law enforcement reforms and successfully dealt with the decades-long stain at Bridgewater State Hospital. We have dramatically increased funding for our schools. And we cut the income tax to 5 percent and dramatically increased our Rainy Day Fund by managing the state’s fiscal affairs with discipline and care.

But today is about the future. This next year needs to be about recovery, not about politics. We are grateful for the chance we have been given to serve the people of this great state and will give it our all between now and the end of 2022.

Charlie Baker and Karyn Polito

我們的計劃

州長查理貝克和副州長白莉朵

致我們的朋友和同事——

和家人討論幾個月之後,我們決定2022年不再尋求連任。這對我們來說是一個極其艱難的決定。我們熱愛這工作,我們尤其尊重和欽佩這個美好州府的人民。擔任麻州州長和副州長是我們曾經歷的最具挑戰性和最充實的工作。我們將永遠感謝這個州的人民給我們這個巨大的榮譽。

我們都經歷了一場異常艱難的病毒大流行,明年將與去年一樣重要,甚至更重要。我們有大量工作要做,以消滅大流行病,讓我們的孩子繼續上學,我們的社區和經濟向前發展。這工作不能也不應該與政治和下一次選舉有關。如果我們參選,就會分心,可能會妨礙我們為麻州每個人所做的許多事情。我們希望專注於復蘇,而不是政治活動可能會衍伸出來的恩怨情仇。

從這場大流行中走出來,我們比以往任何時候都更加敏銳地意識到,當涉及到我們的家人、朋友或我們在這個星球上的時間時,有太少事情我們是可以視作理所當然的。如果做得好,這些工作需要大量的時間和注意力,我們喜歡做這些工作。但我們都想和勞倫、史蒂夫,以及我們的孩子,一起經歷我們家將來的大大小小時刻。

當這個偉大州的選民給我們這個服務機會時,我們是有計劃的。很多計畫。但那並不包括上任頭60天,就遇上下雪30天,或者是天然瓦斯爆炸,或者是全球性的病毒大流行,但是在您們的支持以及麻州人民的創造力和韌性下,我們克服了這些和其他意料之外的危機和事件,推動了我們的州向前發展。

我們決心繼續把主導我們政治格局的黨派劇本放到一旁——與我們在地方政府、立法機關和國會代表團中的同事建立治理夥伴關係。這種兩黨合作的方法,即我們多聽多說,將精力集中在尋找共識而非分歧,避免定義大部分政治話語的公開攻擊和譁眾取寵,讓我們能夠在許多重要問題上取得有意義進展。

我們已帶領全國對抗鴉片類藥物危機,還有更多工作要做,也有資源去做。我們的能源未來 -國家的能源未來 因為我們努力發展深水離岸風力,是更清潔,更有效率的。我們為麻州西部的朋友和鄰居帶來了寬頻。我們在各種住房上做了歷史性投資,制定了一項具有里程碑意義的法律來對抗我們的住房危機,並預計使用大量的聯邦資金來調平未來的房屋市場。我們完成了具有里程碑意義的刑事司法和執法改革,並成功處理了橋水(Bridgewater)州立醫院長達數十年的污點。我們大幅增加了對學校的資助。我們將所得稅降低到 5%,並通過紀律和謹慎地管理本州財政事務,大幅增加了我們的儲備基金。

但今天是關於未來的。明年需要關注復甦,而不是政治。我們感謝有機會為這個偉大州的人民服務,並將在現在到 2022 年底之間全力以赴。

查理·貝克和白莉朵

星期二, 11月 30, 2021

波士頓市長假日列車12/5 下午2點開進華埠

MAYOR WU ANNOUNCES 2021 ENCHANTED TROLLEY TOUR 

Boston’s Enchanted Trolley Tour continues the festive tradition of lighting holiday trees throughout Boston’s neighborhoods

 

BOSTON - Thursday, December 2, 2021 - Mayor Michelle Wu today announced the schedule for this year's Enchanted Trolley Tour, a Boston holiday tradition of lighting holiday trees throughout the City. This year, the Mayor’s Enchanted Trolley Tour will take place on Friday, December 3, Saturday, December 4, and Sunday, December 5, in neighborhoods throughout Boston. This event is presented by Bank of America and includes visits with Santa, tree lightings, and more.

“It’s a joy to participate in our annual holiday trolley tour and tree lightings across the City,” said Mayor Michelle Wu. “The holiday season is a time for friends, family, and neighbors to come together and celebrate, and I am delighted to welcome all to attend this weekend of fun for families and residents.”

The 2021 Mayor’s Enchanted Trolley Tour and Tree Lightings Schedule is as follows: 

Friday, December 3, 2021

·    5:30 p.m. - Mattapan Square, Mattapan

·    6:15 p.m. - Wolcott Square, Readville

·    7 p.m. - Hastings Street Lot, Centre Street, West Roxbury

Saturday, December 4, 2021

·    1 p.m. - Codman Square, Dorchester

·    1:45 p.m. - Hyde Square, Jamaica Plain

·    2:30 p.m - J.P. Monument, Jamaica Plain

·    3:30 p.m. - Brigham Circle, Mission Hill

·    4:15 p.m. - Bolling Building, Roxbury

·    5:30 p.m. - Blackstone Square, South End

·    6:45 p.m. - Oak Square, Brighton

Sunday, December 5, 2021

·    1 p.m. - M Street Park, South Boston

·    2 p.m. - Beach Street & Harrison Avenue, Chinatown

·    3 p.m. - Paul Revere Mall, North End

·    4 p.m. - Thompson Square, Charlestown

·    5 p.m. - Maverick Square, East Boston

·    7 p.m. - Adams Corner, Dorchester

Follow the Mayor’s Office of Tourism, Sports, and Entertainment on social media @VisitBostonCity and visit boston.gov/visiting-boston to learn about more free, family-friendly events happening in the City of Boston.

This is an entirely outdoor, open-air event. It is encouraged, but not required, to wear masks. Individuals who are not fully vaccinated are still at high-risk of spreading COVID-19. If you are not fully vaccinated, you should avoid large social gatherings. If you do plan to attend, avoid congested areas, wear a mask to cover your nose and mouth, and maintain six feet of physical distance as much as possible. To get vaccinated, find a location near you on boston.gov/coronavirus.

2021 CABA Annual Conference 12/4

2021 CABA Annual Conference


2021 CABA Annual Conference

New Era, New Horizon - Explore with Industry Pioneers and Leaders on the New Frontiers in Healthcare Innovation


Date: Dec 4, 2021

Time: 8:45 am - 12:15 pm EST

Agenda and Speaker Profile

This year’s annual conference of CABA will host a collection of industry pioneers and leaders from a diverse background in science and business. These speakers will share exciting stories and developments and offer their insights in fields that will continue to improve human health, including RNA therapeutics, cell therapies, gene editing, and new materials and methods in life sciences. We hope you will join us and explore the new frontiers in healthcare innovation.

 Image

9:00-9:25

Bo Ying, PhD

Founder and CEO, Abogen Biosciences

CABA President (2018-2019)

Bo Ying, Ph.D., is the founder and CEO of Suzhou Abogen Biosciences, dedicated to mRNA-based therapeutics with focus on immune-oncology as well as infectious diseases. Dr. Ying has decades of experiences in drug development, and he is also an expert in drug delivery system such as lipid nanoparticles. He has successfully led team in the process of drug product development, CMC, tech transfer and IND application for a variety of nucleic acid-based therapeutics. As with the ongoing Covid-19 pandemic, Abogen has developed an mRNA-based vaccine and received IND approval from National Center for Drug Evaluation in China. Currently the vaccine product is under phase III clinical trial. Prior to founding Abogen, Dr. Ying has worked as group leader with proven track record of success at different biotech companies in Boston such as Dicerna Pharmaceuticals, Moderna

Therapeutics and Trucode Gene Repair. Dr. Ying received his bachelor and master’s degrees from Fudan University and a Ph.D. degree from Northeastern University in Boston, USA.


 Image

9:25-9:50

Ke Xu, PhD

Founder, Chairman and CEO of VesiCURE

Extracellular Vesicles (EVs) for Drug Development and Delivery

Dr. Ke Xu is the founding CEO of VesiCURE Therapeutics. Dr. Xu received his Ph.D. in Genetics and Development from the University of Texas Southwestern Medical Center at Dallas. After that, he moved to Harvard University for his postdoc training with Drs. Andy McMahon and Doug Melton. In 2014, Dr. Xu joined Biogen to help set up neurodegenerative models using human iPSC and genome editing technologies. From 2016 and before VesiCURE, he worked at Codiak BioSciences, the first exosome therapeutic company in North America, focusing on discovery research and pipeline development.


 Image

9:50-10:15

Shi-Jiang (John) Lu, PhD, MPH

President and CEO of HebeCell Corporation

CAR NK Cells from 3D-iPSC Bioreactor: One Platform Endless Pipelines

Shi-Jiang (John) Lu, PhD, MPH, is the President and CEO of HebeCell Corporation, focusing on the development and clinical translation of regenerative medicine and cell therapy technologies, especially iPS-CAR-NK cells for the treatment of cancer, autoimmune and viral infectious diseases. Before establishing HebeCell, he was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which was acquired by Astellas Pharma in 2016. Dr. Lu is an expert in stem cell biology and regenerative medicine with 20 years of experiences. He has been conducting translational researches and discovery of novel therapeutic strategies utilizing human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and their derivatives. He also has extensive experience in process development and large-scale production of human PSC derivatives under defined conditions for clinical trials. Dr. Lu is the inventor of more than 20 patents in stem cell field: in an analysis of global stem cell patent landscape by Nature Biotechnology in 2014, his patent application and citation ranked No. 7 and No. 5, respectively. In addition to stem cell research, Dr. Lu also has more than 10 year experiences in cancer research. Dr. Lu received his BS degree in Biochemistry from Wuhan University, MSc degree in Oncology/Pathophysiology from Peking Union Medical College, MPH degree in Molecular Toxicology/Environmental Sciences from Columbia University and PhD degree in Molecular Cancer Biology from the University of Toronto.

Therapeutics and Trucode Gene Repair. Dr. Ying received his bachelor and master’s degrees from Fudan University and a Ph.D. degree from Northeastern University in Boston, USA.


 Image

10:25-10:50

Ed Zhang, MBA

Co-founder and Interim CEO of Overland Pharmaceuticals, Venture Partner of Hillhouse Capital


Opportunities and Challenges for a Cross-border Cell Therapy NewCo.

Ed Zhang, MBA, serves as Co-founder and Interim CEO at Overland Pharmaceuticals, and is Venture Partner at Hillhouse Capital. Prior to Overland, Mr. Zhang was VP of Corporate Development at Boston Pharmaceuticals, representing a new biotech business model focused on translational clinical development. As part of its founding team, Mr. Zhang led corporate development and strategic initiatives including establishing partnerships with leading global pharma and biotech companies. Before joining Boston Pharma, Mr. Zhang headed Global Business Development for Sanofi’s Renal Strategic Unit, and was Director of Commercial Operations and Strategic Development at Genzyme before its acquisition by Sanofi. Mr. Zhang started his career as a medicinal chemist at Pharmacia & Upjohn and now brings over 18 years of biopharma industrial experience to Overland. Mr. Zhang holds an MBA from Kellogg School of Management at Northwestern University, an MS in chemistry from Binghamton University, and a BS from Nanjing University.


 Image

10:50-11:15

Eric von Hofe, PhD

President and COO of AffyImmune Therapeutics


Affinity Tune and Track CAR T Cell Technology for Solid Tumors

Eric von Hofe, Ph.D., has over 25 years of experience in biotechnology with a focus on cancer immunotherapy and technology development. Before joining AffyImmune Therapeutics, he led development efforts at Antigen Express advancing the clinical development of novel cancer immunotherapies. Prior to that he held positions of increasing responsibility at Millennium Pharmaceuticals aligning novel technology initiatives with genomics-based drug development objectives.


 Image

11:25-11:50

Tasuku Kitada, PhD

President and Head of R&D of Strand Therapeutics


Progamming mRNA for Cancer Immunotherapy

Dr. Tasuku Kitada is President and Head of R&D of Strand Therapeutics. He co-founded Strand and serves on its Board of Directors. Prior to Strand, Dr. Kitada was Senior Biotechnology Analyst at Candriam Investors Group, where he conducted due diligence for the company’s multi-billion-dollar biopharma public equity investment strategy. At Candriam, he focused on cell and gene therapy companies, and also covered numerous oncology companies. Currently, Dr. Kitada continues to serve Candriam Investors Group as an advisor. Prior to Candriam, Dr. Kitada was a researcher at the Synthetic Biology Center at MIT, where he became the first scientist to create synthetic gene circuits using synthetic mRNA. This was the first demonstration of post-transcriptional circuits that can be “wired” to create a variety of networks of increasing complexity, which enabled cell type specific expression as well as small-molecule based control of gene expression from synthetic mRNA. This important research led to publications in Science, Nature Biotechnology, and Nature Chemical Biology. The mRNA synthetic biology platform developed from this research has been exclusively licensed to Strand. Dr. Kitada holds a Ph.D. in Molecular Biology from the University of California, Los Angeles and a B.S. in Biophysics and Biochemistry from the University of Tokyo.


 Image

11:50-12:15

David Lebwohl, PhD

EVP and CMO of Intellia Therapeutics


CRISPR/Cas9 In Vivo Genome Editing for Transthyretin Amyloidosis: First Clinical Results

Dr. David Lebwohl is the Chief Medical Officer at Intellia Therapeutics, a genome editing company. Before Intellia, Dr. Lebwohl was the Chief Medical Officer at Semma Therapeutics Inc., and led drug development teams at Novartis Pharmaceuticals and Bristol Myers Squibb. At Novartis, he was Senior Vice President and Program Head, CAR-T Teams, responsible for the development of the breakthrough

therapy Kymriah® (tisagenlecleucel), approved for leukemia and lymphoma. Under his leadership,

the blockbuster drug Afinitor® (everolimus) was approved for metastatic breast, neuroendocrine, and

kidney cancer as well as the rare genetic disease tuberous sclerosis. Dr. Lebwohl received an AB in

Biochemical Sciences from Harvard College and an MD from Yale University. He completed his

fellowship training at Memorial Sloan Kettering Cancer Center in medical oncology and hematology

and his residency in internal medicine at the Brigham and Women’s Hospital in Boston.



线上会议

Zoom Meeting

12/04/2021

8:45 am - 12:15 pm EST

ID: 87540625701

Passcode: 718858



扫码或点击“阅读原文”

直达会议


CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.